THE ROLE OF MICRORNA-200C IN CHEMORESISTANT BREAST CANCER
DOI : 10.24269/ijhs.v4i2.2423
Breast cancer is a non-communicable diseases and also major health problem in the world. Based on data from WHO in 2012, the incidence of breast cancer reported as 1.67 million cases. One cause of highest morbidity and mortality in breast cancer is chemoresistancy. Many pathways could cause chemoresistant in breast cancer. The one of pathways are from genetic such as miR-200c. Base on the other study, mir-200c act an apoptosis inducer and inhibit metastasis in chemoresistant breast cancer cells. The mir-200c act the role in specific target cells in chemoresistant breast cancer. Meanwhile, the expression of miR-200c induces Mesenchymal Epithelial Transition (MET) by inhibits ZEB 1 or 2 and TGF-β2 as anti-metastases in chemoresistant breast cancer. miR-200c has a promising potential as a new treatment for chemoresistant breast cancer, because of its potent pro-apoptotic and anti-metastatic properties.
Breast Cancer, miR-200c, Chemoresistant, Mesenchymal Epithelial Transition (MET)
- A. B. S. Satyarsa, “Potential of Fucoidan From Brown Seaweeds (Sargassum sp.) as Innovation Therapy on Breast Cancer,” J. Med. Heal., vol. 2, no. 3, pp. 909–19, 2019, doi: 10.28932/jmh.v2i3.1235.
- World Health Organization (WHO), Prevention Cancer Control: knowledge into action: WHO guide for effective programmes: module (2). Geneva: World Health Organization, 2012.
- International Agency for Research on Cancer (IARCH)/WHO, “Estimated cancer incidence, mortality, and prevalence worldwide in 2012,” 2012. https://publications.iarc.fr/Databases/ Iarc-Cancerbases/GLOBOCAN- 2012-Estimated-Cancer-Incidence- Mortality-And-Prevalence- Worldwide-In-2012-V1.0-2012 (accessed Jan. 28, 2020).
- A. Kamdje et al., “New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers,” World J. Clin. Cases, vol. 2, no. 12, p. 769, 2014, doi: 10.12998/wjcc.v2.i12.769.
- A. Satyarsa, S. Suryantari, P. Gumilang, I. Supadmanaba, and P. Adiputra, “Potensi mikrosfer kombinasi fukoidan dan mirna-200c sebagai inovasi penatalaksanaan kanker payudara kemoresisten,” Maj. Kedokt. Andalas, vol. 43, no. 1, pp. 57–70, 2019.
- R. Pinto, S. Summa, B. Pilato, and S. Tommasi, “DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer,” Curr. Mol. Med., vol. 14, no. 1, pp. 45–57, 2014, doi: 10.2174/15665240136661312031014 05.
- Breast Cancer Organization, “What are the Side Effects of Chemotherapy?,” Breast Cancer Organization, 2012. http://www.breastcancer.org/question s/chemotherapy (accessed Jan. 20, 2020).
- Y. Shimono et al., “Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells,” Cell, vol. 138, no. 3, pp. 592–603, 2009, doi: 10.1016/j.cell.2009.07.011.
- J. Chen, W. Tian, H. Cai, H. He, and Y. Deng, “Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer,” Med. Oncol., vol. 29, no. 4, pp. 2527–2534, 2012, doi: 10.1007/s12032-011-0117-4.
- S. Wiranata, M. Yani, A. Satyarsa, I. Ardiana, and P. Adiputra, “Potency of Combination of Fucoidan Microsphere and MiRNA-200b as Therapy in Chemoresistant Breast Cancer,” J. Med. Heal., vol. 2, no. 5, pp. 103–10, 2020.
- Y. Chen et al., “MiRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin- mediated PTEN/Akt signaling” Mol. MedRep,vol.7,no.5,pp.15791584,201 3,doi:10.3892/mmr.2013.1403.
- R. Neves et al., “Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells,” BMC Res. Notes, vol. 3, 2010, doi: 10.1186/1756-0500-3-219.
- L. Roncati, G. Barbolini, A. M. Gatti, T. Pusiol, F. Piscioli, and A. Maiorana, “The Uncontrolled Sialylation is Related to Chemoresistant Metastatic Breast Cancer,” Pathol. Oncol. Res., vol. 22, no. 4, pp. 869–873, 2016, doi: 10.1007/s12253-016-0057-6.
- S. Chuthapisith, J. Eremin, M. El- Sheemey, and O. Eremin, “Breast cancer chemoresistance: Emerging importance of cancer stem cells,” Surg.Oncol.,vol.19,no.1,pp.27-32, 2010,doi:10.1016/j.suronc.2009.01.4.
- D. X. He et al., “Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer,” Sci. Rep., vol. 6, no. 1, pp. 1–1, 2016, doi: 10.1038/srep24706.
- K. M. Gligorich et al., “Development of a screen to identify selective small molecules active against patient- derived metastatic and chemo- resistant breast cancer cells,” Breast Cancer Res., vol. 15, no. 4, 2013, doi: 10.1186/bcr3452.
- J. Zhang and L. Ma, “MicroRNA control of epithelial-mesenchymal transition and metastasis,” Cancer Metastasis Rev., vol. 31, no. 3–4, pp. 653–662, 2012, doi: 10.1007/s10555- 012-9368-6.
- S. M. Park, A. B. Gaur, E. Lengyel, and M. E. Peter, “The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2,” Genes Dev., vol. 22, no. 7, pp. 894–907, 2008, doi: 10.1101/gad.1640608.
- S. Hyun et al., “Conserved MicroRNA miR-8/miR-200 and Its Target USH/FOG2 Control Growth by Regulating PI3K,” Cell, vol. 139, no. 6, pp. 1096–1108, 2009, doi: 10.1016/j.cell.2009.11.020.
- J. Wang, M. Yang, Y. Li, and B. Han, “The Role of MicroRNAs in the Chemoresistance of Breast Cancer,” Drug Dev.Res.,vol.76, no. 7, pp. 368– 374,2015,doi:10.1002/ddr.21275.
- M. Garofalo and C. M. Croce, “MicroRNAs as therapeutic targets in chemoresistance,” Drug Resist. Updat., vol. 16, no. 3–5, pp. 47–59, 2013, doi: 10.1016/j.drup.2013.05.001.
- B. W.-D. et al., “MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer,” Int. J. Cancer, vol. 135, no. 6, pp. 1356– 1368, 2014, doi: 10.1002/ijc.28782 LK - http://rug.on.worldcat.org/atoztitles/li nk/?sid=EMBASE&issn=10970215& id=doi:10.1002%2Fijc.28782&atitle= MiR-200c+suppresses+TGF- %CE%B2+signaling+and+counteract s+trastuzumab+resistance+and+meta stasis+by+targeting+ZNF217+and+Z EB1+in+breast+cancer&stitle=Int.+J. +Cancer&title=International+Journal +of+Cancer&volume=135&issue=6 &spage=1356&epage=1368&aulast= Bai&aufirst=Wen-Dong&auinit=W.- D.&aufull=Bai+W.- D.&coden=IJCNA&isbn=&pages=13 56- 1368&date=2014&auinit1=W&auinit m=-D.
- D. P. Bartel, “MicroRNAs: Genomics, Biogenesis, Mechanism, and Function,” Cell, vol. 116, no. 2, pp. 281–297, 2004, doi: 10.1016/S0092-8674(04)00045-5.
- C. Wang et al., “Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK-3β/β- catenin signaling,” Theranostics, vol. 6, no. 8, pp. 1205– 1219, 2016, doi: 10.7150/thno.15083.
- V. P. Tryndyak, F. A. Beland, and I. P. Pogribny, “E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells,” Int. J. Cancer, vol. 126, no. 11, pp. 2575– 2583, 2010, doi: 10.1002/ijc.24972.
- G. Moussavou et al., “Anticancer effects of different seaweeds on human colon and breast cancers,” Mar. Drugs, vol. 12, no. 9, 2014, doi: 10.3390/md12094898.
- N. Ruocco, S. Costantini, S. Guariniello, and M. Costantini, “Polysaccharides from the marine environment with pharmacological, cosmeceutical and nutraceutical potential,” Molecules, vol. 21, no. 5, 2016, doi: 10.3390/molecules21050551.
- D. Serpico, L. Molino, and S. Di Cosimo, “MicroRNAs in breast cancer development and treatment,” Cancer Treat. Rev., vol. 40, no. 5, pp. 595–604, 2014, doi: 10.1016/j.ctrv.2013.11.002.
- J. Duanmu, J. Cheng, J. Xu, C. J. Booth, and Z. Hu, “Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy,” Br. J. Cancer, vol. 104, no. 9, pp. 1401–1409, 2011, doi: 10.1038/bjc.2011.88.
- J. Zhang et al., “β-elemene reverses chemoresistance of breast cancer via regulating MDR-related MicroRNA expression,” Cell. Physiol. Biochem., vol. 34, no. 6, pp. 2027–2037, 2014, doi: 10.1159/000366398.
- H. Y. Cho et al., “Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress,” Cancer Lett., vol. 282, no. 1, pp. 87–97, 2009, doi: 10.1016/j.canlet.2009.03.007.
- F. Kopp, P. S. Oak, E. Wagner, and A. Roidl, “miR-200c Sensitizes Breast Cancer Cells to Doxorubicin Treatment by Decreasing TrkB and Bmi1 Expression,” PLoS One, vol. 7, no. 11, 2012, doi: 10.1371/journal.pone.0050469.
- P. W. H. Frings et al., “Elimination of the chemotherapy resistant subpopulation of 4T1 mouse breast cancer by haploidentical NK cells cures the vast majority of mice,” Breast Cancer Res. Treat., vol. 130, no. 3, pp. 773–781, 2011, doi: 10.1007/s10549-011-1355-z.
- S. N. Fedorov, S. P. Ermakova, T. N. Zvyagintseva, and V. A. Stonik, “Anticancer and cancer preventive properties of marine polysaccharides: Some results and prospects,” Mar. Drugs, vol. 11, no. 12, pp. 4876– 4901, 2013, doi: 10.3390/md11124876.
- C. Song et al., “miR-200c inhibits breast cancer proliferation by targeting KRAS,” Oncotarget, vol. 6, no. 33, pp. 34968–34978, 2015, doi: 10.18632/oncotarget.5198.
- P. Ceppi et al., “Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer,” Mol. Cancer Res., vol. 8, no. 9, pp. 1207–1216, 2010, doi: 10.1158/1541-7786.MCR-10-0052.
- E. N. Howe, D. R. Cochrane, and J. K. Richer, “The miR-200 and miR- 221/222 microRNA families: Opposing effects on epithelial identity,” J. Mammary Gland Biol. Neoplasia, vol. 17, no. 1, pp. 65–77, 2012, doi: 10.1007/s10911-012-9244- 6
- G. J. Hurteau, J. A. Carlson, S. D. Spivack, and G. J. Brock, “Overexpression of the MicroRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E- cadherin,” Cancer Res., vol. 67, no. 17, pp. 7972–7976, 2007, doi: 10.1158/0008-5472.CAN-07-1058.
- G. J. Hurteau, J. A. Carlson, E. Roos, and G. J. Brock, “Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E- cadherin expression,” Cell Cycle, vol. 8, no. 13, pp. 2064–2069, 2009, doi: 10.4161/cc.8.13.8883.
- J. Knezevic, A. D. Pfefferle, I. Petrovic, S. B. Greene, C. M. Perou, and J. M. Rosen, “Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential,” Oncogene, vol. 34, no. 49, pp. 5997– 6006, 2015, doi: 10.1038/onc.2015.48.
- E. N. Howe, D. R. Cochrane, and J. K. Richer, “Targets of miR-200c mediate suppression of cell motility and anoikis resistance,” Breast Cancer Res., vol. 13, no. 2, 2011, doi: 10.1186/bcr2867.
- R. Schickel, S. M. Park, A. E. Murmann, and M. E. Peter, “miR- 200c regulates induction of apoptosis through CD95 by targeting FAP-1.,” Mol. Cell, vol. 38, no. 6, pp. 908– 915, 2010, doi: 10.1016/j.molcel.2010.05.018.
- L. Liu et al., “MiR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down- regulation of BMI-1 and E2F3,” J. Transl. Med., vol. 12, no. 1, 2014, doi: 10.1186/s12967-014-0305-z.
- D. Chen et al., “MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial- mesenchymal transition,” J. Ovarian Res., vol. 6, no. 1, 2013, doi: 10.1186/1757-2215-6-50.
- P. A. Hubbard, C. Moody, and R. Murali, “Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: Emerging therapeutic opportunities,” Front. Physiol., vol. 5, no. Nov, 2014, doi: 10.3389/fphys.2014.00478.
- D. S. Yu et al., “MiR-200c regulates ROS-induced apoptosis in murine BV-2 cells by targeting FAP-1,” Spinal Cord, vol. 53, no. 3, pp. 182– 189, 2015, doi: 10.1038/sc.2014.185.
- A. Mitra, L. Mishra, and S. Li, “EMT, CTCs and CSCs in tumor relapse and drug-resistance,” Oncotarget, vol. 6, no. 13, pp. 10697–10711, 2015, doi: 10.18632/oncotarget.4037.
- Q. Wu, Z. Yang, Y. Nie, Y. Shi, and D. Fan, “Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches,” Cancer Lett., vol. 347, no. 2, pp. 159–166, 2014, doi: 10.1016/j.canlet.2014.03.013.
- R. U. Takahashi, H. Miyazaki, and T. Ochiya, “The roles of microRNAs in breast cancer,” Cancers (Basel)., vol. 7, no. 2, pp. 598–616, 2015, doi: 10.3390/cancers7020598.
Copyright (c) 2020 Indonesian Journal for Health Sciences
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.